Work

Direct Ras G12C inhibitors: crossing the rubicon

Year: 2019
Type: editorial
Abstract: Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered 'undruggable'. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.
Language: English
Open Access status: hybrid
Estimated APC paid: $3,367
OpenAlex ID: W2955131133
Cites: 10
Cited by: 42
Related to: 10